The Biological Potential Hidden in Inclusion Bodies.

in vitro in vivo inclusion body matrix metalloproteinase-9 polymeric micelle stability

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 21 01 2020
revised: 12 02 2020
accepted: 13 02 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 23 2 2020
Statut: epublish

Résumé

Inclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. Nevertheless, IBs have been, so far, exclusively sifted by their biological activity in vitro to be considered in further protein-based treatments in vivo. Matrix metalloproteinase-9 (MMP-9) protein, which has an important role facilitating the migration of immune cells, was used as model protein. The MMP-9 IBs were compared with their soluble counterpart and with MMP-9 encapsulated in polymeric-based micelles (PM) through ionic and covalent binding. The soluble MMP-9 and the MMP-9-ionic PM showed the highest activity values in vitro. IBs showed the lowest activity values in vitro, but the specific activity evolution in 50% bovine serum at room temperature proved that they were the most stable format. The data obtained with the use of an air-pouch mouse model showed that MMP-9 IBs presented the highest in vivo activity compared to the soluble MMP-9, which was associated only to a low and a transitory peak of activity. These results demonstrated that the in vivo performance is the addition of many parameters that did not always correlate with the in vitro behavior of the protein of interest, becoming especially relevant at evaluating the potential of IBs as a protein-based nanomaterial for therapeutic purposes.

Identifiants

pubmed: 32075316
pii: pharmaceutics12020157
doi: 10.3390/pharmaceutics12020157
pmc: PMC7076398
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
ID : RTA2012-00028-C02 and RTA2015-00064-C02
Organisme : Agència de Gestió d'Ajuts Universitaris i de Recerca
ID : 2017SGR-229
Organisme : European Social Fund
ID : -
Organisme : CERCA Programme (Generalitat de Catalunya)
ID : -
Organisme : Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
ID : predoctoral fellowship FPI-INIA (L.G.R.)
Organisme : Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
ID : postdoctoral fellowship FPI-INIA (E.G.F.)
Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : postdoctoral fellowship (J.S.F.)
Organisme : Institució Catalana de Recerca i Estudis Avançats
ID : ICREA Academia (A.V.)

Références

J Mol Biol. 2002 May 24;319(1):173-81
pubmed: 12051944
J Clin Invest. 1999 Dec;104(11):1507-15
pubmed: 10587514
Biomaterials. 2016 Nov;107:102-14
pubmed: 27614162
Adv Sci (Weinh). 2019 Jul 24;6(18):1900849
pubmed: 31559131
Microbiology. 2006 Sep;152(Pt 9):2611-8
pubmed: 16946256
Acta Biomater. 2014 Mar;10(3):1354-9
pubmed: 24361427
Nanomedicine (Lond). 2013 Oct;8(10):1587-99
pubmed: 23394133
Trends Biochem Sci. 2017 Sep;42(9):726-737
pubmed: 28254353
Nanomedicine (Lond). 2015;10(5):873-91
pubmed: 25816885
Microb Cell Fact. 2012 Jun 11;11:76
pubmed: 22686540
Adv Mater. 2020 Feb;32(7):e1907348
pubmed: 31879981
Nanotechnology. 2010 May 21;21(20):205101
pubmed: 20413834
Int J Nanomedicine. 2013;8:4745-56
pubmed: 24379662
FEMS Microbiol Rev. 2019 Jan 1;43(1):53-72
pubmed: 30357330
Acta Biomater. 2016 Oct 1;43:230-239
pubmed: 27452157
Trends Biotechnol. 2012 Feb;30(2):65-70
pubmed: 22037492
Adv Mater. 2012 Apr 3;24(13):1742-7
pubmed: 22410789
Sci Rep. 2018 Sep 17;8(1):13917
pubmed: 30224788
Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72
pubmed: 23547785
FASEB J. 2006 Mar;20(3):444-54
pubmed: 16507762
Nanomedicine (Lond). 2015;10(18):2881-91
pubmed: 26370294
J Control Release. 2018 Jun 10;279:29-39
pubmed: 29641987
Immunobiology. 2006;211(3):137-48
pubmed: 16530081
Mol Microbiol. 2000 Mar;35(5):1042-51
pubmed: 10712686

Auteurs

Laia Gifre-Renom (L)

Department of Ruminant Production, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), 08140 Caldes de Montbui, Spain.

Joaquin Seras-Franzoso (J)

Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Diana Rafael (D)

Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.

Fernanda Andrade (F)

Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-180 Porto, Portugal.
INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, 4200-180 Porto, Portugal.

Olivia Cano-Garrido (O)

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.
Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.

Francesc Martinez-Trucharte (F)

Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.

Estefania Ugarte-Berzal (E)

Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, University of Leuven, 3000 Leuven, Belgium.

Erik Martens (E)

Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, University of Leuven, 3000 Leuven, Belgium.

Lise Boon (L)

Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, University of Leuven, 3000 Leuven, Belgium.

Antonio Villaverde (A)

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.
Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.

Ghislain Opdenakker (G)

Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, University of Leuven, 3000 Leuven, Belgium.

Simó Schwartz (S)

Drug Delivery & Targeting, CIBBIM-Nanomedicine, Vall d'Hebron Institut of Research (VHIR), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain.
Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain.

Anna Arís (A)

Department of Ruminant Production, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), 08140 Caldes de Montbui, Spain.

Elena Garcia-Fruitós (E)

Department of Ruminant Production, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), 08140 Caldes de Montbui, Spain.

Classifications MeSH